Document Detail

Verteporfin PDT for non-standard indications--a review of current literature.
MedLine Citation:
PMID:  20162298     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Verteporfin photodynamic therapy (PDT) is approved for the treatment of predominantly classic subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration (AMD), as well as for subfoveal CNV due to pathologic myopia and ocular histoplasmosis syndrome. Verteporfin PDT addresses the underlying pathology of ocular vascular disorders through its angio-occlusive mechanism of action, which reduces both visual acuity loss and the underlying leakage associated with lesions. Verteporfin PDT has also been associated with encouraging treatment outcomes in case studies involving patients with choroidal vascular disorders such as polypoidal choroidal vasculopathy, central serous chorioretinopathy, choroidal haemangioma, angioid streaks, and inflammatory CNV, i.e. conditions currently considered as non-standard indications of verteporfin PDT. In many studies, outcomes were better than expected based on the natural courses of each of these conditions. Although the anti-vascular endothelial growth factor (VEGF) therapies, ranibizumab and pegaptanib, have been approved for CNV due to AMD, their role in these other choroidal vascular disorders remains to be established. We summarize current literature that has documented the use of verteporfin PDT in these conditions.
CONCLUSIONS: The complex pathogenesis of CNV provides a rationale for investigating combination approaches comprising verteporfin PDT and anti-VEGF therapies. Randomized controlled studies are warranted to confirm the preliminary results of verteporfin PDT as a monotherapy or in combination with anti-VEGF therapies in the treatment of a variety of choroidal vascular conditions.
Wai Man Chan; Tock-Han Lim; Alfredo Pece; Rufino Silva; Nagahisa Yoshimura
Related Documents :
18824038 - Treating lysosomal storage disorders: current practice and future prospects.
22470208 - Reticulate acropigmentation of dohi: a case report with insight into genodermatoses wit...
14750048 - Effect of risperidone on prolactinoma--a case report.
10755248 - Diagnosing collagenous colitis: does it make a difference?
12061478 - Difficulties associated with wrist disorders--a qualitative study.
21993868 - Completed suicides in 47 psychiatric hospitals in germany - results from the agate-study.
Publication Detail:
Type:  Journal Article; Review     Date:  2010-02-17
Journal Detail:
Title:  Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie     Volume:  248     ISSN:  1435-702X     ISO Abbreviation:  Graefes Arch. Clin. Exp. Ophthalmol.     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-03-29     Completed Date:  2010-06-23     Revised Date:  2013-05-20    
Medline Journal Info:
Nlm Unique ID:  8205248     Medline TA:  Graefes Arch Clin Exp Ophthalmol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  613-26     Citation Subset:  IM    
Department of Ophthalmology, HK Sanatorium Hospital, Happy Valley, Hong Kong.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioid Streaks / drug therapy
Central Serous Chorioretinopathy / drug therapy
Choroid Diseases / drug therapy*
Choroid Neoplasms / drug therapy
Choroidal Neovascularization / drug therapy
Hemangioma / drug therapy
Peripheral Vascular Diseases / drug therapy
Photosensitizing Agents / therapeutic use*
Porphyrins / therapeutic use*
Retinal Diseases / drug therapy*
Reg. No./Substance:
0/Photosensitizing Agents; 0/Porphyrins; 129497-78-5/verteporfin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Thrombophilic risk factors in the pathogenesis of non-arteritic anterior ischemic optic neuropathy p...
Next Document:  Ultrasonic Doppler measurements of blood flow velocity of rabbit retinal vessels using a 45-MHz need...